Insider buying last 90 days
No open-market insider purchases were filed for IMCR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IMCR insider filing, plotted on the chart in Gekko.Open IMCR in Gekko
Gekko Brief
AI summaryOct 12 closeImmunocore's week centered on clinical and commercial updates rather than a single catalyst. The company completed enrollment of 540 patients in its TEBE-AM Phase 3 trial, announced on 8 October, with shares falling 1.90% after hours on the news. Separately, Immunocore reported first-half 2026 KIMMTRAK sales growth of 16%, reaching $223 million, with Q2 sales up 18% year over year to $116 million. The company also confirmed upcoming appearances at investor conferences, including the Chardan Genetic Medicines Conference and Cantor Global event.
IMCR closed at $29.04, down 1.2%, sitting between its 50-day average of $33.42 and 200-day average of $31.98, reflecting a mixed trend. Shares have declined 10.9% over one month, 13.2% over three months, and 14% over the past year. The GekkoIndex reads 71.7, placing the stock in the Buying zone, down 2.4 over five days. The gap to Gekko Fair Value of $43.97 stands at 34% below current price.
Earnings are scheduled for 5 November 2026, before the open, 24 days away and inside a typical 20-trading-day holding window; the last report on 6 August showed a beat with a 2.1% reaction. Seasonally, the next 20 trading days have averaged a 9.3% return over 5 years, with gains in all 5 of those years. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Analyst consensus includes 4 buy and 2 hold ratings across 6 firms, with a consensus target of $62.73.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Immunocore price vs fair value
Close $29.04200-day averageGekko Fair Value $43.97
Immunocore quick facts
- Market cap
- $1.48B
- P/E ratio
- —
- Forward P/E
- 23.8
- EPS, TTM
- −$0.36
- Revenue, TTM
- $430.8M
- Profit margin
- -4.2%
- Dividend yield
- —
- Beta
- 0.82
- Volume
- 219,725 avg 440,731
- 1-year return
- −14.0%
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±8.5%
- 50-day average
- $33.42
- 200-day average
- $31.98
- Next earnings
- Nov 5 before open
- Shares outstanding
- 51.50M
Immunocore swing-trade checklist
Immunocore scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $29.04 sits between the 50-day ($33.42) and 200-day ($31.98) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.7, Buying
Reading 71.7 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
34.0% below
Price is 34% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+9.3% on average
From this point in the calendar, the next 20 trading days averaged +9.3% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Immunocore stock chart and price history
Immunocore closed at $29.04 on Oct 12, 2026, −14.0% over the past year, inside a 52-week range of $27.56 to $40.71.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −10.9%
- 3 months
- −13.2%
- 6 months
- −7.7%
- 1 year
- −14.0%
The full IMCR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IMCR in Gekko
Follow Immunocore through every session
Put IMCR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IMCR in GekkoFree for 7 days. No credit card required.
About Immunocore
Immunocore develops immune-based therapies aimed at serious illnesses, spanning several forms of cancer, infectious disease and autoimmune conditions. It has moved beyond research into commercial sales with KIMMTRAK, a treatment for uveal melanoma that cannot be surgically removed or has spread to other parts of the body.
Beyond its marketed product, the company runs a set of clinical programs. In oncology, IMC-C103C and IMC-F106C are both being tested in early-stage dose escalation studies across a wide range of solid tumors, among them lung, gastric, head and neck, ovarian, endometrial, breast and skin cancers, as well as synovial sarcoma. On the infectious disease side, IMC-I109V is in early clinical trials for chronic hepatitis B, while IMC-M113V remains in preclinical work targeting HIV. The company is also pursuing candidates intended to suppress immune activity in a targeted way for autoimmune disease.
Immunocore trades under the ticker IMCR.
- Sector
- Health technology
- Website
- immunocore.com
Immunocore GekkoIndex: the smart money zone
Immunocore’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.7, in the Buying zone, down 2.4 points over five sessions.
71.7Buying
Down 2.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 48 | −0.9% | −4.0% | ||
| Accumulation | 268 | +0.7% | +0.7% | ||
| Neutral | 297 | −1.3% | −2.8% | ||
| Distribution | 22 | −1.8% | −7.5% | ||
| Selling | 0 | Not available | |||
Average IMCR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the IMCR price, zone by zone.Track IMCR in Gekko
Is Immunocore stock overvalued? Gekko Fair Value
Immunocore trades 34.0% below Gekko Fair Value of $43.97, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Immunocore shares are worth, recalculated every trading day.
$43.97
Gekko Fair Value, Oct 10, 2026
34.0% Undervalued
At the end of Aug 2026 the price was 30.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IMCR in Gekko
Immunocore insider and Congress trading
No open-market insider purchases were filed for Immunocore, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IMCR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IMCR, plotted on the chart in Gekko.Open IMCR in Gekko
Immunocore earnings: next date and track record
Immunocore reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- −$0.12
- Revenue estimate
- $152.9M
5 of 8reports beat the EPS estimate
±4.2%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.02 est −$0.01 | $115.9M est $148.8M | +2.1% |
| May 6, 2026 | $0.25 est −$0.26 | $145.0M est $145.4M | +6.2% |
| Feb 25, 2026 | −$0.60 est −$0.28 | $140.1M est $144.5M | −4.9% |
| Nov 6, 2025 | $0.02 est −$0.30 | $103.7M est $142.2M | +8.8% |
| Aug 7, 2025 | −$0.20 est −$0.21 | $134.3M est $134.2M | −0.4% |
| May 7, 2025 | $0.10 est −$0.35 | $121.5M est $121.8M | +6.2% |
| Feb 26, 2025 | −$0.37 est −$0.16 | $105.2M est $85.49M | +1.3% |
| Nov 6, 2024 | $0.17 est −$0.35 | $107.4M est $110.0M | +4.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Immunocore stock forecast and analyst price targets
Analysts’ average 12-month price target for Immunocore is $62.73, +116.0% from the last close, from 6 firms rating the stock in the last 90 days.
$62.73consensus 12-month target, +116.0% from the last close
Now $29.04Avg $62.73
Low $35High $100
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 21 | H.C. Wainwright | $100 | +244.4% |
| Aug 21 | J.P. Morgan | $50 | +72.2% |
| Aug 12 | H.C. Wainwright | $100 | +244.4% |
| Aug 7 | Mizuho Securities | $35 | +20.5% |
| Aug 7 | Morgan Stanley | $43 | +48.1% |
−4.0%average 20-day move after past Buying readings
+9.3%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Immunocore seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Immunocore averaged +9.3% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.9% | 4 of 5 |
| Next 10 trading days | +3.6% | 4 of 5 |
| Next 15 trading days | +5.0% | 3 of 5 |
| Next 20 trading days | +9.3% | 5 of 5 |
| Next 30 trading days | +11.3% | 3 of 5 |
For scale, IMCR’s typical 20-trading-day move in either direction is about 8.5%.
Immunocore market cap and key statistics
Immunocore’s market cap is $1.48B and revenue of $430.8M over the last twelve months.
Valuation
- Market cap
- $1.48B
- Forward P/E
- 23.8
- EPS, TTM
- −$0.36
- Gekko Fair Value
- $43.97
Trading
- Volume
- 219,725
- Avg volume, 20 days
- 440,731
- 52-week high
- $40.71
- 52-week low
- $27.56
- Shares outstanding
- 51.50M
Financials
- Revenue, TTM
- $430.8M
- Profit margin
- -4.2%
- Return on equity
- -4.5%
- Quarterly earnings growth, YoY
- +150.0%
Risk and income
- Beta
- 0.82
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±8.5%
Immunocore stock news this week
Coverage of Immunocore this week reads positive: 3 positive, 3 neutral and 1 negative headlines.
- Immunocore completed 540-patient enrollment. Immunocore stock fell 1.90 percent.AD HOC NEWS, Oct 8
- Immunocore to Present at Upcoming Investor ConferencesMoomoo, Oct 8
- One passive holder reports sole voting power over 1.73 million Immunocore (IMCR) shares.Stock Titan, Oct 7
- Immunocore stock reports 16 percent first half revenue growthAD HOC NEWS, Oct 7
- Price to earnings forward of Immunocore Holdings plc – NASDAQ:IMCRTradingView, Oct 6
- Immunocore stock reports 18 percent KIMMTRAK sales growthAD HOC NEWS, Oct 5
Immunocore stock FAQ
What is Immunocore’s market cap?
Immunocore’s market cap is $1.48B at the Oct 12, 2026 close of $29.04, with 51.50M shares outstanding.
What is the Immunocore stock forecast?
The consensus analyst 12-month price target for Immunocore is $62.73, +116.0% from the last close. Of the 6 firms that rated the stock in the last 90 days, 4 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Immunocore stock overvalued or undervalued?
On Gekko’s estimate Immunocore is undervalued: the Oct 12, 2026 close of $29.04 is 34.0% below Gekko Fair Value of $43.97. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Immunocore report earnings next?
Immunocore is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of −$0.12 per share on revenue of $152.9M. Immunocore beat the earnings estimate in 5 of its last 8 reports, moving 4.2% on average across the report.
What is Immunocore’s 52-week high and low?
Immunocore’s 52-week high is $40.71 and its 52-week low is $27.56; it closed at $29.04 on Oct 12, 2026, −14.0% over the past year. Over the last five years the shares peaked at $76.98 on Feb 1, 2024.
Is Immunocore stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Immunocore the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.